DOCSLIB.ORG

Sodium Selenate Hazard Summary Identification

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sodium Selenate Hazard Summary Identification Common Name: SODIUM SELENATE CAS Number: 13410-01-0 RTK Substance number: 1726 DOT Number: UN 2630 Date: November 2001 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY WORKPLACE EXPOSURE LIMITS * Sodium Selenate can affect you when breathed in and The following exposure limits are for Selenium compounds may be absorbed through the skin. (measured as Selenium): * Contact can irritate the skin and eyes. * Breathing Sodium Selenate can irritate the nose, throat OSHA: The legal airborne permissible exposure limit 3 and lungs causing coughing, wheezing and/or shortness of (PEL) is 0.2 mg/m averaged over an 8-hour breath. workshift. * High exposure can cause headache, nausea, vomiting, NIOSH: The recommended airborne exposure limit is coated tongue, metallic taste and garlic odor on the breath. 3 * Repeated exposure can cause pallor, nervousness and 0.2 mg/m averaged over a 10-hour workshift. mood changes. ACGIH: The recommended airborne exposure limit is * Sodium Selenate may damage the liver and kidneys and 3 affect the heart. 0.2 mg/m averaged over an 8-hour workshift. * The above exposure limits are for air levels only. When IDENTIFICATION skin contact also occurs, you may be overexposed, even Sodium Selenate is a white, sand-like solid. It is used as a though air levels are less than the limits listed above. medication and an insecticide. WAYS OF REDUCING EXPOSURE REASON FOR CITATION * Where possible, enclose operations and use local exhaust * Sodium Selenate is on the Hazardous Substance List ventilation at the site of chemical release. If local exhaust because it is regulated by OSHA and cited by ACGIH, ventilation or enclosure is not used, respirators should be DOT, NIOSH, DEP and EPA. worn. * Definitions are provided on page 5. * Wear protective work clothing. * Wash thoroughly immediately after exposure to Sodium HOW TO DETERMINE IF YOU ARE BEING Selenate and at the end of the workshift. EXPOSED * Post hazard and warning information in the work area. In The New Jersey Right to Know Act requires most employers addition, as part of an ongoing education and training to label chemicals in the workplace and requires public effort, communicate all information on the health and employers to provide their employees with information and safety hazards of Sodium Selenate to potentially exposed training concerning chemical hazards and controls. The workers. federal OSHA Hazard Communication Standard, 1910.1200, requires private employers to provide similar training and information to their employees. * Exposure to hazardous substances should be routinely evaluated. This may include collecting personal and area air samples. You can obtain copies of sampling results from your employer. You have a legal right to this information under OSHA 1910.1020. * If you think you are experiencing any work-related health problems, see a doctor trained to recognize occupational diseases. Take this Fact Sheet with you. SODIUM SELENATE page 2 of 6 This Fact Sheet is a summary source of information of all Any evaluation should include a careful history of past and potential and most severe health hazards that may result from present symptoms with an exam. Medical tests that look for exposure. Duration of exposure, concentration of the substance damage already done are not a substitute for controlling and other factors will affect your susceptibility to any of the exposure. potential effects described below. --------------------------------------------------------------------------- Request copies of your medical testing. You have a legal right to this information under OSHA 1910.1020. HEALTH HAZARD INFORMATION Mixed Exposures Acute Health Effects * Because more than light alcohol consumption can cause The following acute (short-term) health effects may occur liver damage, drinking alcohol can increase the liver immediately or shortly after exposure to Sodium Selenate: damage caused by Sodium Selenate. * Contact can irritate the skin and eyes. WORKPLACE CONTROLS AND PRACTICES * Breathing Sodium Selenate can irritate the nose, throat and lungs causing coughing, wheezing and/or shortness of Unless a less toxic chemical can be substituted for a hazardous breath. substance, ENGINEERING CONTROLS are the most effective way of reducing exposure. The best protection is to Chronic Health Effects enclose operations and/or provide local exhaust ventilation at The following chronic (long-term) health effects can occur at the site of chemical release. Isolating operations can also some time after exposure to Sodium Selenate and can last for reduce exposure. Using respirators or protective equipment is months or years: less effective than the controls mentioned above, but is sometimes necessary. Cancer Hazard * Sodium Selenate may cause mutations (genetic changes). In evaluating the controls present in your workplace, consider: * There is no evidence that Sodium Selenate causes cancer in (1) how hazardous the substance is, (2) how much of the animals. This is based on test results presently available to substance is released into the workplace and (3) whether the New Jersey Department of Health and Senior Services harmful skin or eye contact could occur. Special controls from published studies. should be in place for highly toxic chemicals or when significant skin, eye, or breathing exposures are possible. Reproductive Hazard * There is no evidence that Sodium Selenate affects In addition, the following control is recommended: reproduction. This is based on test results presently available to the New Jersey Department of Health and * Where possible, automatically transfer Sodium Selenate Senior Services from published studies. from drums or other storage containers to process containers. Other Long-Term Effects * High exposure can cause headache, nausea, vomiting, Good WORK PRACTICES can help to reduce hazardous exposures. The following work practices are recommended: coated tongue, metallic taste and garlic odor on the breath. * Repeated exposure can cause pallor, nervousness and mood * Workers whose clothing has been contaminated by Sodium changes. Selenate should change into clean clothing promptly. * Sodium Selenate may damage the liver and kidneys and * Do not take contaminated work clothes home. Family affect the heart. members could be exposed. * Contaminated work clothes should be laundered by MEDICAL individuals who have been informed of the hazards of exposure to Sodium Selenate. Medical Testing * Eye wash fountains should be provided in the immediate If symptoms develop or overexposure is suspected, the work area for emergency use. following are recommended: * If there is the possibility of skin exposure, emergency shower facilities should be provided. * Urine test for Selenium (should be less than * On skin contact with Sodium Selenate, immediately wash 100 micrograms per liter of urine). or shower to remove the chemical. At the end of the * EKG. workshift, wash any areas of the body that may have * Liver and kidney function tests. contacted Sodium Selenate, whether or not known skin contact has occurred. SODIUM SELENATE page 3 of 6 * Do not eat, smoke, or drink where Sodium Selenate is * If while wearing a filter or cartridge respirator you can handled, processed, or stored, since the chemical can be smell, taste, or otherwise detect Sodium Selenate, or if swallowed. Wash hands carefully before eating, drinking, while wearing particulate filters abnormal resistance to applying cosmetics, smoking, or using the toilet. breathing is experienced, or eye irritation occurs while * Use a vacuum or a wet method to reduce dust during clean- wearing a full facepiece respirator, leave the area up. DO NOT DRY SWEEP. immediately. Check to make sure the respirator-to-face seal is still good. If it is, replace the filter or cartridge. If the PERSONAL PROTECTIVE EQUIPMENT seal is no longer good, you may need a new respirator. * Be sure to consider all potential exposures in your WORKPLACE CONTROLS ARE BETTER THAN workplace. You may need a combination of filters, PERSONAL PROTECTIVE EQUIPMENT. However, for prefilters or cartridges to protect against different forms of a some jobs (such as outside work, confined space entry, jobs chemical (such as vapor and mist) or against a mixture of done only once in a while, or jobs done while workplace chemicals. controls are being installed), personal protective equipment * Where the potential for overexposure exists, use a NIOSH may be appropriate. approved supplied-air respirator with a full facepiece operated in a pressure-demand or other positive-pressure OSHA 1910.132 requires employers to determine the mode. For increased protection use in combination with an appropriate personal protective equipment for each hazard and auxiliary self-contained breathing apparatus operated in a to train employees on how and when to use protective pressure-demand or other positive-pressure mode. equipment. * Exposure to 1 mg/m3 (as Selenium) is immediately dangerous to life and health. If the possibility of exposure The following recommendations are only guidelines and may above 1 mg/m3 (as Selenium) exists, use a NIOSH not apply to every situation. approved self-contained breathing apparatus with a full facepiece operated in a pressure-demand or other positive- Clothing pressure mode. * Avoid skin contact with Sodium Selenate. Wear protective gloves and clothing. Safety equipment suppliers/ manufacturers can provide recommendations
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7,211,656 B2 Mukerji Et Al
    US00721 1656B2 (12) United States Patent (10) Patent No.: US 7,211,656 B2 Mukerji et al. (45) Date of Patent: May 1, 2007 (54) DESATURASE GENES, ENZYMES ENCODED Doerks et al., TIG 14(6): 248-250, Jun. 1998.* THEREBY, AND USES THEREOF Smith et al. Nature Biotechnology 15: 1222-1223, Nov. 15, 1997.* Brenner, S.E., TIG 15(4): 132-133, Apr. 1999.* (75) Inventors: Pradip Mukerji, Gahanna, OH (US); Bork et al., TIG 12(10): 425-427, Oct. 1996.* Suzette L. Pereira, Westerville, OH Leslie, C. G. et al., “Dietary (n-9) Eicosatrienoic Acid from a (US); Yung-Sheng Huang, Upper Cultured Fungus Inhibits Leukotriene B4 Synthesis in Rats and the Arlington, OH (US) Effect Is Modified by Dietary Linoleic Acid' ', Amer Journ of Clin Nutrit, 126(6): 1534-1540 (1996). Jareonkitmongkol, S., et al., “Production of an Eicosapentaenoic (73) Assignee: Abbott Laboratories, Abbott Park, IL Acid-Containing Oil by a A12 Desaturase-Defective Mutant of (US) Mortierella alpina 1S-4”, Journ of the Amer Oil Chemists Soc. 70(2): 119-123 (1993). (*) Notice: Subject to any disclaimer, the term of this Pereira, S.L., et al., “A novel (p-fatty acid desaturase involved in the patent is extended or adjusted under 35 biosynthesis of eicosapentaenoic acid”. The Biohem Journ, U.S.C. 154(b) by 444 days. 378(2):665-671 (2004). Ziboh, V.A., et al., Metabolism of polyunsaturated fatty acids by (21) Appl. No.: 10/060,793 skin epidermal enzymes: generation of anti-inflammatory and antiproliferative metabolites 1-3, Amer Journ of Clin Nutri, (22) Filed: Jan.
    [Show full text]
  • Felix Ekness
    ABSTRACT A Synthetic Biology Approach to Engineering Bacterial Two- Component Systems for Sensor Development and Discovery of Anti-Virulence Agents by Felix Ekness Bacterial two-component systems (TCSs) are the largest family of signal transduction pathways that enable bacteria to sense a diversity of stimuli including small peptides, environmental pollutants, and light. Canonical TCSs are composed of a transmembrane sensor histidine kinase (SK) that converts stimulus detection into phosphorylation of a cognate response regulator (RR). Upon phosphorylation, the cytoplasmic RR binds target output promoters, hereby modulating gene expression. TCSs are valuable sensors for synthetic biology due to their diverse sensing capabilities and straightforward transduction of detected stimulus into transcriptional regulation. TCSs are also emerging targets for novel therapeutic development due to their extensive role in regulating bacterial virulence and antibiotic resistance. Although TCSs are exciting sensors for synthetic biology and targets for therapeutic applications, most TCSs remain difficult to harness for applications and study due to output promoters that are unknown, subject to cross- regulation, or silent in heterologous hosts. In the first portion of my work, I develop a method to overcome the hurdles in characterizing and utilizing TCSs as biosensors. Through the framework of synthetic biology, I demonstrate that the two largest families of RR DNA binding domains (DBDs) can be interchanged with remarkable flexibility, enabling the corresponding TCSs to be rewired to synthetic output promoters. In collaboration with Kristina Daeffler, we exploit this plasticity to eliminate cross-regulation and in collaboration with Brian Landry, we un-silence a gram-negative TCS in a gram-positive host and engineer a sensor with over 1,300-fold activation.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Antidepressant Effect of ß-Hydroxy-ß-Methylbutyrate
    (19) TZZ Z_T (11) EP 2 745 708 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 25.06.2014 Bulletin 2014/26 A23L 1/305 (2006.01) A23L 1/29 (2006.01) A61K 31/19 (2006.01) A61P 25/24 (2006.01) (21) Application number: 12382531.7 (22) Date of filing: 24.12.2012 (84) Designated Contracting States: • Barranco-Pérez, Alejandro AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 18110 LAS GABIAS (Granada) (ES) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Rueda Cabrera, Ricardo PL PT RO RS SE SI SK SM TR 18008 GRANADA (ES) Designated Extension States: • Bespalov, Anton BA ME 69118 HEIDELBERG (DE) • Behl, Berthold (71) Applicant: Abbott Laboratories, Inc. 67098 BAD DUERKHEIM (DE) Abbott Park, IL 60064 (US) • Van Gaalen, Marcel M. 67433 NEUSTADT AN DER WEINSTRASSE (DE) (72) Inventors: • Ramírez, María (74) Representative: Ungria López, Javier 18003 GRANADA (ES) Avda. Ramón y Cajal, 78 28043 Madrid (ES) (54) Antidepressant effect of ß-hydroxy-ß-methylbutyrate (57) A method of treating or preventing depression method of treating or preventing a condition which can using β-hydroxy-β-methylbutyrate (HMB) is described. be improved or prevented by the activation of mTOR sig- The method includes administering an effective amount naling by administering an effective amount of HMB or a of HMB or a pharmaceutically acceptable salt thereof to pharmaceutically acceptable salt thereof to a subject in a subject in need thereof. The HMB can be administered need thereof. as part of a nutritional composition.
    [Show full text]
  • Investigation Into the Effect on Structure of Oxoanion Doping in Na2m(SO4)2·2H2O Driscoll, Laura; Wright, Adrian; Kendrick, Emma; Slater, Peter
    University of Birmingham Investigation into the effect on structure of oxoanion doping in Na2M(SO4)2·2H2O Driscoll, Laura; Wright, Adrian; Kendrick, Emma; Slater, Peter DOI: 10.1016/j.jssc.2016.07.004 License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) Document Version Peer reviewed version Citation for published version (Harvard): Driscoll, L, Wright, A, Kendrick, E & Slater, P 2016, 'Investigation into the effect on structure of oxoanion doping in Na M(SO ) ·2H O', Journal of Solid State Chemistry, vol. 242, no. Part 1, pp. 103-111. https://doi.org/10.1016/j.jssc.2016.07.0042 4 2 2 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked 7/9/2016 General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain. Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
    [Show full text]
  • Investigation Into the Effect on Structure of Oxoanion Doping in Na2m(SO4)2·2H2O Driscoll, Laura; Wright, Adrian; Kendrick, Emma; Slater, Peter
    University of Birmingham Investigation into the effect on structure of oxoanion doping in Na2M(SO4)2·2H2O Driscoll, Laura; Wright, Adrian; Kendrick, Emma; Slater, Peter DOI: 10.1016/j.jssc.2016.07.004 License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) Document Version Peer reviewed version Citation for published version (Harvard): Driscoll, L, Wright, A, Kendrick, E & Slater, P 2016, 'Investigation into the effect on structure of oxoanion doping in Na M(SO ) ·2H O', Journal of Solid State Chemistry, vol. 242, no. Part 1, pp. 103-111. https://doi.org/10.1016/j.jssc.2016.07.0042 4 2 2 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked 7/9/2016 General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain. Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
    [Show full text]
  • Potassium Selenate, Sodium Selenate,Sodium Selenite
    26 March 2015 EMA/CVMP/187590/2015 Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR) Potassium selenate (All food producing species) Sodium selenate (All food producing species) Sodium selenite (All food producing species) Selenate and selenite salts have a widespread prophylactic and therapeutic use in veterinary medicines against diseases and disorders related to selenium deficiencies in animals. The substances were previously evaluated by the Committee for Medicinal Products for Veterinary Use in 1997, leading to the establishment of “No MRL required” classifications in all food producing species with no restrictions on the route of administration1. On 12 May 2014 the European Commission requested the European Medicines Agency to review the established maximum residue limits. This request followed the CVMPs recommendation of 10 April 2014 on barium selenate and focused on concerns relating to potential consumer exposure to residues at the injection site. Based on the available data, the Committee for Medicinal Products for Veterinary Use recommended, on 4 December 2014, the maintenance of the existing MRL classifications for potassium selenate, sodium selenate and sodium selenite in all food producing species. 1 Commission Regulation (EU) No 37/2010, of 22.12.2009 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. Summary of the scientific discussion for the establishment of MRLs Substance name: Potassium selenate, sodium selenate and sodium selenite Therapeutic class: Alimentary tract and metabolism/mineral supplements Procedure number: EMEA/V/MRL/003225/MODF/0002 Applicant: European Commission Target species: All food producing species Intended therapeutic indication: Selenium deficiency Route(s) of administration: Oral/Intramuscular 1.
    [Show full text]
  • California Official Feed Terms
    CALIFORNIA OFFICIAL FEED TERMS Alfalfa Products Barley Products Chopped Alfalfa Ground Barley Alfalfa Meal Rolled Barley Alfalfa Leaf Meal Ground Light Barley Forage Meal Rolled Light Barley Alfalfa Stem Meal Barley Mixed Feed Alfalfa Pellets, Cubes, Wafers Barley Hulls Alfalfa Nutrient Concentrate Barley Feed Concentrated Alfalfa Solubles Hulled Barley Ground Hulled Barley Almond Hull Products Rolled Hull Barley Almond Hulls Almond Hull and Shell Beet Products Almond Shell Dried Beet Pulp Wet Beet Pulp Animal Products Molasses Dried Beet Pulp Meat Meal Molasses Dried Beet Pulp Product Meat and Bone Meal Blood Meal Brewers’ and Distiller’s Products Poultry By-Product Meal Brewers Dried Grains Poultry Hatchery By-Product Brewers Wet Grains Hydrolyzed Poultry Feathers Malt Sprouts Dry Rendered Tankage Malt Cleanings Dried Meat Solubles Malt Hulls Fleshing Hyrdolysate Dried Spent Hops Animal By-Product Meal Molasses Distillers Dried Solubles Hydrolyzed Hair Potato Distillers Dried Residue Hydrolyzed Leather Meal Distillers Dried Solubles Sprayed Dried Animal Blood Distillers Dried Grains Egg Shell Meal Condensed Distillers Solubles Egg Product Poultry Meal Coconut Products Blood Meal, Flash Dried Coconut Meal Glandular Meal and Extracted Glandular Meal Copra Meal Animal Plasma Coconut Meal, Solvent Extracted Ensiled Paunch Product Copra Meal, Solvent Extracted Leather Hydrolyzate Corn Products Processed Animal Waste Products Corn Bran Dried Poultry Waste Corn Feed Meal Dried Poultry Litter Ground Corn Dried Ruminant Waste Corn Meal Processed
    [Show full text]
  • Selenium in Drinking-Water
    WHO/HSE/WSH/10.01/14 Selenium in Drinking-water Background document for development of WHO Guidelines for Drinking-water Quality Selenium in Drinking-water Background document for development of WHO Guidelines for Drinking-water Quality © World Health Organization 2011 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications—whether for sale or for non-commercial distribution—should be addressed to WHO Press at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • FCC 10, Second Supplement the Following Index Is for Convenience and Informational Use Only and Shall Not Be Used for Interpretive Purposes
    Index to FCC 10, Second Supplement The following Index is for convenience and informational use only and shall not be used for interpretive purposes. In addition to effective articles, this Index may also include items recently omitted from the FCC in the indicated Book or Supplement. The monographs and general tests and assay listed in this Index may reference other general test and assay specifications. The articles listed in this Index are not intended to be autonomous standards and should only be interpreted in the context of the entire FCC publication. For the most current version of the FCC please see the FCC Online. Second Supplement, FCC 10 Index / Allura Red AC / I-1 Index Titles of monographs are shown in the boldface type. A 2-Acetylpyrrole, 21 Alcohol, 90%, 1625 2-Acetyl Thiazole, 18 Alcohol, Absolute, 1624 Abbreviations, 7, 3779, 3827 Acetyl Valeryl, 608 Alcohol, Aldehyde-Free, 1625 Absolute Alcohol (Reagent), 5, 3777, Acetyl Value, 1510 Alcohol C-6, 626 3825 Achilleic Acid, 25 Alcohol C-8, 933 Acacia, 602 Acid (Reagent), 5, 3777, 3825 Alcohol C-9, 922 ªAccuracyº, Defined, 1641 Acid-Hydrolyzed Milk Protein, 22 Alcohol C-10, 390 Acesulfame K, 9 Acid-Hydrolyzed Proteins, 22 Alcohol C-11, 1328 Acesulfame Potassium, 9 Acid Calcium Phosphate, 240 Alcohol C-12, 738 Acetal, 10 Acid Hydrolysates of Proteins, 22 Alcohol C-16, 614 Acetaldehyde, 11 Acidic Sodium Aluminum Phosphate, Alcohol Content of Ethyl Oxyhydrate Acetaldehyde Diethyl Acetal, 10 1148 Flavor Chemicals (Other than Acetaldehyde Test Paper, 1636 Acidified Sodium Chlorite
    [Show full text]
  • Food Supplements: Permitted Vitamins and Minerals
    Food Supplements List of Vitamins and Minerals which may be used in the manufacture of food supplements in the EU Digital ISBN 978 0 7504 7646 1 © Crown copyright 2012 WG15822 Important note This document was correct at the time of publishing. The lists of vitamins and minerals permitted for use in food supplements is subject to change. Please ensure you check the European Commission’s website for any amendments to the list (Click here) Vitamins and minerals which may be used in the manufacture of food supplements as permitted by Directive 2002/46/EC relating to food supplements1 Vitamins Unit of Minerals Unit of measurement measurement Vitamin A μg RE Calcium mg Vitamin D μg Magnesium mg Vitamin E mg α-TE Iron mg Vitamin K μg Copper μg Vitamin B1 mg Iodine μg Vitamin B2 mg Zinc mg Niacin mg NE Manganese mg Pantothenic acid mg Sodium mg Vitamin B6 mg Potassium mg Folic acid2 μg Selenium μg Vitamin B12 μg Chromium μg Biotin μg Molybdenum μg Vitamin C mg Fluoride mg Chloride mg Phosphorus mg Boron mg Silicon mg 1 As amended by Regulation (EC) No. 1137/2008 (OJ L311, 21.11.2008, p.1; Regulation (EC) No. 1170/2009 (OJ L314, 1.12.2009, p.36); and Regulation (EC) No. 1161/2011 (OJ L296, 15.11.2011, p.29) 2 Folic acid is the term included in Annex I of Commission Directive 2008/100/EC of 28 October 2008 amending Council Directive 90/496/EEC on nutrition labelling for foodstuffs as regards recommended daily allowances, energy conversion factors and definitions for nutrition labelling purposes and covers all forms of folates." Vitamins VITAMIN
    [Show full text]
  • Minimum Lethal Dose of Selenium, As Sodium Selenite, for Horses, Mules, Cattle, and Swine '
    MINIMUM LETHAL DOSE OF SELENIUM, AS SODIUM SELENITE, FOR HORSES, MULES, CATTLE, AND SWINE ' By W. T. MILLER, associate veterinarian^ Animal Disease Station^ Bureau of Animal Industry^ and K. T. WILLIAMS, formerly associate chemist^ Division of Soil Chemistry and Physics^ Bureau of Plant Industry^ United States Department of Agriculture 2 INTRODUCTION Following the discovery of selenium in numerous plants grown in certain areas of the north-central Great Plains and its identification as the cause of so-called alkali disease of livestock in those areas, a number of experiments have been undertaken to test its toxicity. Most of this work was designed to study the effect of continued feed- ing of small doses of selenium in various forms to small experimental animals. The disease produced in this way was of the subacute or chronic type. In a few studies, however, large single doses of sele- nium have been administered, resulting in the acute type of poisoning. It appears that only small laboratory animals have previously been used for this work. Franke and Moxon,^ using rats, found that the minimum fatal dose (smallest dose that killed 75 percent or more of the animals in 48 hours) of selenium, in the form of sodium selenite, injected intraperitoneally was 1.5 mg. per pound of body weight. Of sodium selenate, the minimum fatal dose was found to be 2.5 mg. per pound of body weight. Smith, Stohlman, and Lillie,^ using rabbits, found that the fatal dose of selenium, in the form of sodium selenite or selenate, when administered orally was 1.5 to 2.0 mg.
    [Show full text]